SPAC110.05 Antibody

What is SPAC110.05 and why is it significant for research?

SPAC110.05 is a protein-coding gene in the fission yeast Schizosaccharomyces pombe (strain 972 / ATCC 24843). This gene is of interest to researchers studying fundamental cellular processes in eukaryotes. Based on genomic analysis, SPAC110.05 has been identified in the fission yeast genome sequencing project . The significance of studying this protein lies in addressing the knowledge gap of the "dark proteome" - the substantial portion of proteins whose functions remain poorly characterized or unknown, even in well-studied model organisms like fission yeast .

Antibodies against SPAC110.05 provide essential tools for investigating this protein's:

• Expression patterns

• Localization within cells

• Interactions with other proteins

• Functional roles in cellular processes

What types of SPAC110.05 antibodies are currently available for research?

The primary type of SPAC110.05 antibody commercially available is a rabbit polyclonal antibody raised against recombinant Schizosaccharomyces pombe SPAC110.05 protein . This antibody is:

• Generated in rabbits

• Polyclonal in nature (contains multiple antibody clones targeting different epitopes)

• Purified using antigen affinity chromatography

• Formulated in liquid form with storage buffer containing glycerol and PBS

• Designed for applications including ELISA and Western blot (WB)

Custom antibody generation services are also available for researchers with specific requirements beyond standard catalog offerings .

What is the recommended storage and handling protocol for SPAC110.05 antibodies?

For optimal performance and longevity of SPAC110.05 antibodies, follow these storage and handling guidelines:

Proper storage and handling are critical for maintaining antibody functionality, as improper conditions can lead to denaturation, aggregation, or contamination that negatively impact experimental results .

How should I validate the specificity of a SPAC110.05 antibody for my research?

Validation of SPAC110.05 antibody specificity is crucial for reliable experimental results. A comprehensive validation approach includes:

• Western blot analysis with positive and negative controls

  • Use lysates from wild-type S. pombe (positive control)

  • Compare with SPAC110.05 deletion mutants (negative control)

  • Verify single band of expected molecular weight

• Immunoprecipitation followed by mass spectrometry

  • Similar to the approach used in antibody validation for SpA5 (Fig. 3D)

  • Confirm that the precipitated protein is indeed SPAC110.05

• Cross-reactivity testing

  • Test against related proteins to ensure specificity

  • Check reactivity against human proteins if using in comparative studies

• Peptide competition assay

  • Pre-incubate antibody with purified SPAC110.05 protein or peptide

  • Observe elimination of signal in subsequent applications

• Orthogonal validation using genetic approaches

  • Use tagged versions of SPAC110.05 and detect with both anti-tag and anti-SPAC110.05 antibodies

  • Validate using strains with altered SPAC110.05 expression levels

This multi-faceted approach provides rigorous validation similar to what has been described for other antibodies in research settings .

What are the optimal conditions for using SPAC110.05 antibody in Western blot applications?

For optimal Western blot results with SPAC110.05 antibody, follow these methodological guidelines:

Sample Preparation:

• Extract proteins using RIPA buffer or specialized yeast protein extraction protocols

• Include protease inhibitors to prevent degradation

• Normalize protein concentration (15-30 μg total protein per lane)

Electrophoresis and Transfer:

• Use 10-12% SDS-PAGE gels for optimal separation

• Transfer to PVDF or nitrocellulose membrane at 100V for 1 hour or 30V overnight at 4°C

Blocking and Antibody Incubation:

Detection:

• Use ECL reagent appropriate for your expected signal strength

• Expose to film or use digital imaging system

• Include molecular weight markers to verify target band size

Controls:

• Include positive control (wild-type S. pombe lysate)

• Include negative control (SPAC110.05 knockout strain if available)

• Consider using loading control antibody (e.g., anti-tubulin or anti-actin)

These conditions may require optimization based on your specific experimental system and antibody lot .

How can I optimize SPAC110.05 antibody dilution for different applications?

Finding the optimal antibody dilution is critical for maximizing signal-to-noise ratio. Here's a methodological approach for different applications:

Western Blot Titration:

• Prepare a consistent amount of protein sample

• Test dilution series: 1:500, 1:1000, 1:2000, 1:5000

• Process identically and compare signal intensity and background

• Select the dilution that provides clear specific signal with minimal background

ELISA Titration:

• Coat plates with consistent antigen concentration

• Prepare a series of antibody dilutions: 1:1000, 1:2000, 1:5000, 1:10000

• Generate a titration curve plotting OD values against antibody concentration

• Select dilution from the linear portion of the curve

Immunohistochemistry/Immunocytochemistry:

• Start with manufacturer's recommended dilution

• Test a range around this concentration (e.g., 2× more concentrated to 5× more dilute)

• Include appropriate negative controls

• Select dilution providing specific staining with minimal background

Factors Affecting Optimal Dilution:

• Antibody affinity and concentration

• Abundance of target protein

• Sample preparation method

• Detection system sensitivity

• Background interference in your specific sample

Document optimal conditions for reproducibility in future experiments .

How can SPAC110.05 antibody be used in protein interaction studies?

SPAC110.05 antibody can be leveraged for studying protein interactions through several advanced methodologies:

Co-Immunoprecipitation (Co-IP):

• Lyse fission yeast cells in non-denaturing buffer to preserve protein complexes

• Pre-clear lysate with protein A/G beads

• Incubate with SPAC110.05 antibody (5-10 μg per reaction)

• Capture with protein A/G beads

• Wash extensively to remove non-specific interactions

• Elute and analyze by Western blot or mass spectrometry

• Validate interactions with reciprocal Co-IP using antibodies against putative interacting partners

Proximity Ligation Assay (PLA):

• Fix and permeabilize cells on microscope slides

• Block non-specific binding sites

• Incubate with SPAC110.05 antibody and antibody against suspected interacting protein

• Apply PLA probes (secondary antibodies with DNA oligonucleotides)

• Ligate and amplify DNA if proteins are in close proximity

• Detect amplified DNA with fluorescent probes

• Visualize using fluorescence microscopy

Chromatin Immunoprecipitation (ChIP) if nuclear function is suspected:

• Cross-link protein-DNA complexes in vivo

• Lyse cells and shear chromatin

• Immunoprecipitate with SPAC110.05 antibody

• Reverse cross-links and purify DNA

• Analyze by qPCR or sequencing

These approaches can be integrated with high-throughput proteomic techniques to place SPAC110.05 within the broader protein interaction network of fission yeast, similar to approaches used in other studies .

What considerations are important when using SPAC110.05 antibody in conjunction with fluorescent microscopy?

When planning immunofluorescence experiments with SPAC110.05 antibody, consider these critical methodological aspects:

Fixation and Permeabilization:

• Test multiple fixation methods:

  • 4% paraformaldehyde (preserves structure but may reduce epitope accessibility)

  • Methanol fixation (better for some nuclear proteins)

  • Combined formaldehyde/methanol approach for fission yeast

• Optimize permeabilization for yeast cell wall (may require enzymatic digestion with zymolyase or lysing enzymes)

Antibody Selection and Controls:

• Use highly specific SPAC110.05 primary antibody

• Select secondary antibody with appropriate fluorophore based on:

  • Microscope filter sets available

  • Spectral overlap with other fluorophores if multiplexing

  • Signal strength needed (consider brightness of different fluorophores)

• Essential controls:

  • No primary antibody control

  • Isotype control

  • SPAC110.05 deletion strain (if available)

  • Peptide competition control

Co-localization Studies:

• Choose compatible fluorophores with minimal spectral overlap

• Consider using strains with known compartment markers (e.g., nuclear, ER, Golgi)

• Use appropriate co-localization algorithms and statistics

Live Cell vs. Fixed Imaging:

• Fixed: Better for precise localization and co-staining

• Live: If examining dynamics, consider fusion proteins instead of antibodies

Image Acquisition and Analysis:

• Use consistent exposure settings between samples and controls

• Employ deconvolution for improved resolution

• Quantify localization patterns using appropriate software

• Consider super-resolution techniques for detailed subcellular localization

These approaches are similar to those used in other studies examining protein localization in fission yeast .

How can I integrate SPAC110.05 antibody studies with genomic and phenotypic data in fission yeast?

Integrating antibody-based protein studies with genomic and phenotypic data creates a more comprehensive understanding of SPAC110.05 function. Here's a methodological framework:

Correlation with Phenotypic Data:

• Compare protein expression/localization patterns detected by antibody with phenotypes of SPAC110.05 deletion mutants

• Examine if protein levels correlate with specific stress responses or growth conditions

• Cross-reference with broad phenotypic profiling data available for fission yeast

Integration with Transcriptomic Data:

• Correlate protein levels (detected by Western blot) with mRNA expression under various conditions

• Investigate if post-transcriptional regulation occurs by comparing protein vs. RNA levels

• Use antibody to study protein expression in mutants affecting gene regulation

Functional Genomic Approaches:

• Use antibody to analyze SPAC110.05 levels or modifications in deletion library screens

• Combine with synthetic genetic array (SGA) data to identify genetic interactions

• Correlate with high-throughput phenotypic data to generate hypotheses about function

Network Analysis:

• Place SPAC110.05 in protein interaction networks using antibody-based techniques

• Correlate with machine learning-derived functional predictions using NET-FF approach

• Use "guilt by association" to predict functions based on known interactors

Example Integrated Workflow:

• Identify conditions where SPAC110.05 deletion shows phenotypes

• Use antibody to determine if protein levels/localization changes under those conditions

• Perform Co-IP with antibody to identify interacting partners

• Cross-reference with predicted Gene Ontology terms

• Design targeted experiments to test functional hypotheses

This integrated approach mirrors comprehensive studies done with other fission yeast proteins .

What are common issues with SPAC110.05 antibody specificity and how can they be addressed?

Researchers may encounter several specificity issues when working with SPAC110.05 antibody. Here are methodological approaches to identify and resolve these problems:

Cross-Reactivity Issues:

• Problem: Antibody binds to proteins other than SPAC110.05
  Solution:

  • Perform Western blot with SPAC110.05 deletion strain

  • Use peptide competition assay to confirm specific binding

  • Consider testing the antibody on a protein array to identify cross-reactive proteins

• Problem: Background binding to cell wall components
  Solution:

  • Optimize blocking conditions (test different blocking agents: milk, BSA, normal serum)

  • Increase washing stringency (higher salt concentration or mild detergents)

  • Pre-absorb antibody with cell wall preparation from SPAC110.05 deletion strain

False Negative Results:

• Problem: No signal despite presence of protein
  Solution:

  • Verify epitope accessibility (try different extraction methods)

  • Test different antibody concentrations

  • Try different detection methods with higher sensitivity

  • Consider if post-translational modifications might mask the epitope

Batch-to-Batch Variation:

• Problem: Inconsistent results between antibody lots
  Solution:

  • Maintain detailed records of antibody performance by lot

  • Retain small amounts of well-performing lots as reference

  • Validate each new lot with positive controls

  • Consider developing monoclonal antibodies for critical applications

Validation Strategy Table:

This systematic approach to troubleshooting is similar to validation protocols used for other research antibodies .

How can I determine if the SPAC110.05 antibody is detecting post-translational modifications?

Detecting post-translational modifications (PTMs) of SPAC110.05 requires specialized methodological approaches to distinguish modified forms from the unmodified protein:

Western Blot Analysis:

• Run samples on high-resolution gels (e.g., 8-10% acrylamide with extended run times)

• Look for mobility shifts that might indicate modifications

• Compare with samples treated with:

  • Phosphatase (removes phosphorylation)

  • Deglycosylation enzymes (removes glycosylation)

  • Deubiquitinating enzymes (removes ubiquitin)

• Use modification-specific antibodies (e.g., anti-phosphotyrosine) alongside SPAC110.05 antibody

Mass Spectrometry Approaches:

• Immunoprecipitate SPAC110.05 using the antibody

• Analyze by LC-MS/MS with data acquisition methods optimized for PTM detection

• Search for common modifications including phosphorylation, acetylation, methylation, etc.

• Validate findings with modification-specific antibodies if available

Generation of Modification-Specific Antibodies:

• Identify potential modification sites through:

  • Predictive algorithms

  • Conservation analysis

  • MS data

• Generate peptides with the specific modification of interest

• Raise and purify modification-specific antibodies

• Validate using phosphatase or other enzyme treatments as negative controls

Control Experiments:

• Treat cells with PTM-inducing conditions:

  • Phosphorylation: Osmotic stress, cell cycle synchronization

  • Ubiquitination: Proteasome inhibitors

  • SUMOylation: Heat shock

• Compare detection patterns before and after treatment

• Use mutant strains with altered PTM machinery

This approach mirrors methodologies used for phosphorylation-specific antibody validation in other studies .

What critical controls should be included when validating a new lot of SPAC110.05 antibody?

Thorough validation of each new antibody lot is essential for experimental reproducibility. Include the following methodological controls:

Essential Controls for Western Blot Validation:

Additional Validation Experiments:

• Peptide competition assay:

  • Pre-incubate antibody with excess antigen peptide

  • Apply to Western blot or other application

  • Signal should be absent or significantly reduced

• Cross-reactivity testing:

  • Test on lysates from related species

  • Document any cross-reactivity for reference

  • Particularly important if using in comparative studies

• Application-specific validation:

  • For IP: Confirm pull-down efficiency and specificity

  • For IHC/ICC: Verify localization pattern consistency

  • For ELISA: Generate standard curves and determine detection limits

• Documentation requirements:

  • Record lot number, dilution used, and incubation conditions

  • Archive images of validation results

  • Note any differences from previous lots

  • Update protocols if optimization is required

This comprehensive validation approach ensures reliability and reproducibility, similar to best practices described for antibody validation in research settings .

How does the performance of polyclonal versus monoclonal antibodies differ for SPAC110.05 detection?

When selecting between polyclonal and monoclonal antibodies for SPAC110.05 research, consider these comparative aspects:

Performance Characteristics Comparison:

Methodological Considerations:

• For Western blotting:

  • Polyclonals often provide stronger signal due to multiple epitope binding

  • Monoclonals may give cleaner background but potentially weaker signal

• For immunoprecipitation:

  • Polyclonals can be advantageous for pulling down protein complexes

  • Monoclonals may provide more consistent results across experiments

• For imaging techniques:

  • Monoclonals typically provide more consistent staining patterns

  • Polyclonals may detect denatured protein more effectively

• For post-translational modification studies:

  • Monoclonals can be generated to specifically recognize modified forms

  • Polyclonals may recognize both modified and unmodified forms

Current Status:
Currently, commercially available antibodies for SPAC110.05 are primarily polyclonal . For researchers requiring the advantages of monoclonal antibodies, custom development would be necessary, involving:

• Immunization with recombinant SPAC110.05 protein or peptides

• Hybridoma generation and screening

• Extensive validation similar to that performed for other monoclonal antibodies

This comparison reflects similar considerations applied to antibody selection in other research contexts .

What are the most effective strategies for using SPAC110.05 antibody in chromatin immunoprecipitation (ChIP) experiments?

If SPAC110.05 is suspected to interact with DNA or chromatin-associated proteins, ChIP experiments provide valuable insights. Here's a methodological framework:

Optimization Steps for SPAC110.05 ChIP:

• Cross-linking optimization:

  • Test various formaldehyde concentrations (0.75-3%)

  • Optimize cross-linking time (10-30 minutes)

  • Consider dual cross-linking (formaldehyde + DSG or EGS) for improved protein-protein fixation

• Chromatin fragmentation:

  • Compare sonication vs. enzymatic digestion

  • Target 200-500 bp fragments for optimal resolution

  • Verify fragmentation by agarose gel electrophoresis

• Antibody selection and validation:

  • Test antibody in IP experiments first to confirm pull-down efficiency

  • Perform peptide competition assays to verify specificity

  • Consider multiple antibodies recognizing different epitopes if available

• ChIP protocol optimization:

  • Determine optimal antibody concentration (typically 2-10 μg per reaction)

  • Test various washing stringencies to balance signal vs. background

  • Include appropriate controls:

    • Input DNA (non-immunoprecipitated chromatin)

    • IgG control (non-specific antibody)

    • Positive control (antibody against known chromatin protein)

    • Negative control regions for qPCR

• Analysis methods:

  • ChIP-qPCR: For targeted analysis of specific genomic regions

  • ChIP-seq: For genome-wide binding profile

  • ChIP-exo or ChIP-nexus: For high-resolution binding site identification

Special Considerations for Fission Yeast ChIP:

• Cell wall removal optimization (zymolyase treatment conditions)

• Spheroplast handling to prevent chromatin damage

• Fixation conditions compatible with yeast cell physiology

• Consideration of cell cycle stage for chromatin association

This methodological approach is similar to that used for other chromatin-associated proteins in fission yeast studies .

How can I develop quantitative assays using SPAC110.05 antibody for high-throughput screening?

Developing quantitative high-throughput assays with SPAC110.05 antibody requires optimization of several methodological parameters:

ELISA-Based Quantification:

• Sandwich ELISA development:

  • Coat plates with capture antibody (anti-SPAC110.05 or anti-tag if working with tagged protein)

  • Add cell lysates containing SPAC110.05

  • Detect with SPAC110.05 antibody (if using anti-tag for capture) or biotinylated SPAC110.05 antibody

  • Develop with HRP-conjugated secondary antibody and substrate

• Standard curve generation:

  • Express and purify recombinant SPAC110.05

  • Create standard curve with known concentrations

  • Interpolate unknown samples from standard curve

• Assay optimization parameters:

  • Coating buffer composition and concentration

  • Blocking agent selection (BSA, milk, commercial blockers)

  • Antibody concentrations and incubation times

  • Wash protocol stringency

  • Substrate selection for desired sensitivity range

High-Content Imaging:

• Immunofluorescence optimization:

  • Cell fixation and permeabilization protocol

  • Antibody concentrations and incubation conditions

  • Nuclear counterstain selection

  • Washing protocol to minimize background

• Automated image acquisition and analysis:

  • Define regions of interest (whole cell, nucleus, cytoplasm)

  • Develop quantitative metrics (intensity, localization pattern)

  • Implement machine learning for complex phenotypes

Bead-Based Multiplex Assay:

• Coupling SPAC110.05 antibody to beads:

  • Select optimal coupling chemistry

  • Determine antibody density on beads

  • Validate with known positive and negative samples

• Multiplexing with other markers:

  • Select compatible antibody pairs

  • Test for cross-reactivity

  • Develop compensation protocols for spectral overlap

Assay Validation Metrics:

• Determine Z-factor for assay quality assessment

• Establish intra- and inter-assay coefficients of variation

• Define LLOQ (lower limit of quantification) and ULOQ (upper limit of quantification)

• Test with genetic or chemical perturbations with expected effects

This approach to developing quantitative assays is similar to methodologies used for yeast biopanning and antibody screening in other studies .

How can SPAC110.05 antibody be used in studies of protein degradation and turnover?

Investigating SPAC110.05 protein stability and degradation pathways requires specific methodological approaches using the antibody:

Protein Half-life Determination:

• Cycloheximide chase assay:

  • Treat cells with cycloheximide to block new protein synthesis

  • Collect samples at time intervals (0, 1, 2, 4, 8, 24 hours)

  • Perform Western blot with SPAC110.05 antibody

  • Quantify signal decay to calculate half-life

  • Include control protein with known half-life

• Pulse-chase analysis:

  • Metabolically label cells with 35S-methionine

  • Chase with cold methionine

  • Immunoprecipitate SPAC110.05 at various timepoints

  • Visualize by autoradiography

  • Calculate degradation rate from signal decay

Degradation Pathway Analysis:

• Proteasome inhibition:

  • Treat cells with MG132 or bortezomib

  • Monitor SPAC110.05 levels by Western blot

  • Accumulation suggests proteasomal degradation

• Autophagy inhibition:

  • Treat with bafilomycin A1 or chloroquine

  • Analyze SPAC110.05 levels by Western blot

  • Co-localization with autophagy markers by immunofluorescence

• Ubiquitination analysis:

  • Immunoprecipitate SPAC110.05

  • Probe with anti-ubiquitin antibody

  • Alternatively, express His-tagged ubiquitin

  • Purify ubiquitinated proteins under denaturing conditions

  • Probe for SPAC110.05

Regulated Degradation Studies:

• Stress response:

  • Expose cells to various stresses (oxidative, heat, nutrient deprivation)

  • Monitor SPAC110.05 levels and modifications

  • Correlate with phenotypic data from deletion studies

• Cell cycle analysis:

  • Synchronize cells at different cell cycle stages

  • Analyze SPAC110.05 abundance by Western blot

  • Correlate with known cell-cycle regulated genes

• Post-translational modification correlation:

  • Detect modifications that might trigger degradation

  • Use phospho-specific antibodies if available

  • Test effect of kinase or phosphatase inhibitors

This methodological approach parallel techniques used to study protein stability in other fission yeast proteins, providing insights into regulatory mechanisms controlling SPAC110.05 function .